Compare JFrog Ltd. Ordinary Shares (FROG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JFrog Ltd. Ordinary Shares vs Natera Inc. Common Stock — how do they compare? JFrog Ltd. Ordinary Shares trades at $91.27 (market cap $12.24B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.7× JFrog Ltd. Ordinary Shares's market cap, and JFrog Ltd. Ordinary Shares is more actively traded (1,786,951 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold JFrog Ltd. Ordinary Shares for 5 Days and Natera Inc. Common Stock for 0 Days on average.
| FROG | NTRA | |
|---|---|---|
Market Cap | $12.24B | $57.03B |
Volume | 1,786,951 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $104.03 | $425.64 |
52-Week Low | $34.75 | $179.42 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $11.43B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JFrog (FROG) trades at $99.28, up 0.26% on the day, showing strong technical momentum with a bullish moving average signal and trading near pivot point resistance at $99. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending, while maintaining robust revenue growth projections from $532M in 2025 to $600M in 2026. Recent product announcements at swampUP 2026 focused on AI-era software supply chain security enhancements.
Wall Street maintains strong bullish sentiment with 87.5% buy ratings and a $110.25 consensus price target, representing 11% upside potential. However, negative profitability metrics and insider selling activity present near-term headwinds. The stock's elevated P/S ratio of 19.77 requires continued execution on growth targets to justify valuation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JFrog Ltd. Ordinary Shares
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
